Richard D. Beger Data-verified

Affiliation confirmed via AI analysis of OpenAlex, ORCID, and web sources.

High Impact

Branch Chief

NCTR

Last publication 2025 Last refreshed 2026-05-16

faculty

48 h-index 220 pubs 13,646 cited

Research Areas

Links

ORCID

OverviewAI-generated summary

Richard D. Beger's research program focuses on the application of analytical chemistry techniques, particularly metabolomics and proteomics, within the context of regulatory toxicology and precision medicine. His work investigates the development and implementation of quality assurance and quality control (QA/QC) measures for untargeted metabolic phenotyping. This includes establishing recommendations for analytical quality management and reviewing the use of reference materials for mass spectrometry-based metabolomics and lipidomics.

Beger has contributed to frameworks for reporting transcriptomics and metabolomics data in regulatory toxicology, aligning with emerging technologies in regulatory science. His research also explores the discovery of novel proteomic biomarkers for predicting kidney recovery in patients undergoing dialysis. He has published on the application of UHPLC-MS metabolomics, including tutorials on analysis types and quantification methods, and has explored metabolomics as a translational tool for precision medicine.

His collaborations include work with Lisa Pence, Amy L. Inselman, Kellie A. Woodling, and Gonçalo Gamboa da Costa, all from the National Center for Toxicological Research. Beger's scholarly output is marked by a high impact, evidenced by an h-index of 48 and over 13,000 citations across more than 200 publications.

Metrics

h-index: 48
Publications: 220
Citations: 13,646

Selected Publications

Biomarker-driven drug development for allergic diseases and asthma: An FDA public workshop (2025)

2 citations DOI OpenAlex
Untargeted metabolomics and lipidomics in COVID-19 patient plasma reveals disease severity biomarkers (2024)

4 citations DOI OpenAlex
The incorporation of MALDI mass spectrometry imaging in studies to identify markers of toxicity following in utero opioid exposures in mouse fetuses (2024)

1 citation DOI OpenAlex
Analysis types and quantification methods applied in UHPLC-MS metabolomics research: a tutorial (2024)

20 citations DOI OpenAlex
Identification of Proteomic Biomarkers of Acetaminophen-Induced Hepatotoxicity Using Stable Isotope Labeling (2024)

DOI OpenAlex
The effect of black cohosh extract and risedronate coadministration on bone health in an ovariectomized rat model (2024)

2 citations DOI OpenAlex
Current Practices in LC-MS Untargeted Metabolomics: A Scoping Review on the Use of Pooled Quality Control Samples (2023)

80 citations DOI OpenAlex
Metabolomics evaluation of the photochemical impact of violet-blue light (405 nm) on ex vivo platelet concentrates (2023)

5 citations DOI OpenAlex
Prediction and Experimental Evaluation of the hERG Blocking Potentialof Drugs Showing Clinical Signs of Cardiotoxicity (2022)

1 citation DOI OpenAlex
Quality assurance and quality control reporting in untargeted metabolic phenotyping: mQACC recommendations for analytical quality management (2022)

176 citations DOI OpenAlex
Effects of Serum and Compound Preparation Methods on Delayed Repolarization Evaluation With Human iPSC-CMs (2022)

6 citations DOI OpenAlex
Evaluating Cefoperazone-Induced Gut Metabolic Functional Changes in MR1-Deficient Mice (2022)

3 citations DOI OpenAlex
Reference materials for MS-based untargeted metabolomics and lipidomics: a review by the metabolomics quality assurance and quality control consortium (mQACC) (2022)

121 citations DOI OpenAlex
Serum metabolite profiles predict outcomes in critically ill patients receiving renal replacement therapy (2021)

17 citations DOI OpenAlex
Identification of structural factors that affect binding to cannabinoid receptor type 1 (2021)

1 citation DOI OpenAlex